Nevro Corp.

Nevro Corp. is a medical device company headquartered in Redwood City, California, dedicated to providing innovative solutions for individuals suffering from chronic pain. The company has developed the HF10™ therapy, an advanced neuromodulation platform designed to deliver significant pain relief without the discomfort of paresthesia.

The cornerstone of Nevro's offerings is the Senza® Spinal Cord Stimulation (SCS) System, which utilizes HF10 therapy to treat chronic pain in the trunk and limbs. Unlike traditional SCS therapies that operate at frequencies between 40–60 Hz, HF10 therapy operates at a high frequency of 10 kHz, providing patients with effective pain relief without the tingling sensations commonly associated with other treatments.

Product Portfolio

• Senza II: An enhanced version of the original Senza system, offering improved features for patient comfort and treatment efficacy.
• Senza Omnia: A comprehensive SCS system that delivers a wide range of frequencies and waveforms, allowing for personalized pain management tailored to individual patient needs.
• HFX iQ: An AI-powered pain management platform that adapts therapy programs based on patient responses, aiming to optimize pain relief over time.

Nevro's commitment to innovation is further demonstrated by the development of HFX AdaptivAI, a responsive, personalized pain management platform that powers the HFX iQ SCS system. This platform utilizes artificial intelligence to continuously adjust therapy programs, ensuring optimal pain relief tailored to each patient's unique response.

Regulatory Milestones

The company's dedication to advancing pain management has led to significant regulatory milestones. The Nevro Senza SCS System received the CE mark in 2010, TGA approval in 2011, and FDA approval in 2015, making it commercially available in Europe, Australia, and the United States.

Locations

Nevro operates globally, with its headquarters located at 1800 Bridge Parkway, Redwood City, California, 94065, USA.

Additional locations include:

• West Palm Beach, FL, USA
• Europe
• Australia

Recent Developments

In February 2025, Nevro Corp. was acquired by Globus Medical Inc. for $250 million, marking a significant development in the company's growth and expansion.

Company Mission

Nevro's mission is to help more patients suffering from chronic pain achieve lasting relief through innovative technologies, advanced therapies, and comprehensive support services.

By continually advancing the field of spinal cord stimulation, Nevro aims to improve the quality of life for individuals affected by chronic pain worldwide.